GeneProt Offers Proteins to Serono for Testing and Licensing

Last week, GeneProt of Geneva announced an agreement with Geneva-based biopharmaceutical firm Serono that might lead to a licensing deal for GeneProt’s proteins.

Under the agreement, which will initially last for one year, Serono will receive a set of less than 50 synthesized polypeptides and proteins from GeneProt to test using its screening platform. The company then has an option to license the proteins exclusively.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.